Pharma 2025 _ Event Postponement
We would like to inform you that due to unforeseen circumstances beyond the organizer control, the "12th Edition of the Global Conference on Pharmaceutics and Novel Drug Delivery Systems" (Pharma-2025), originally scheduled for March 13-15, 2025 | Hybrid Event has been postponed. The updated dates and venue are September 11-13, 2025 | Valencia, Spain. For more details, please visit: https://pharmaceuticsconference.com/
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at pharmadds@magnusconference.com or call + 1 (702) 988 2320.
Biological drugs (sometimes known as "biologics" or "originators") are a type of medication that is derived primarily from biological sources. They are one of the most expensive drugs on the market due to their high cost and difficulty in development. Biosimilar drugs are similar to biologic medicines, but they are not an exact reproduction of the biologic and cannot be labelled a “generic” because of the natural variability involved in their development. The introduction of biosimilars was supposed to shake up the pharmaceutical industry, resulting in reduced prices and greater access to drugs. Market access, on the other hand, has been slower than many expected, with some claiming anti-competitive activities as a barrier to entry and expansion.
- Barriers in Developing Biosimilar Drugs
- Global trends in Biosimilar Drug Market
- Regulatory Constraints
John K Maesaka
NYU Langone Hospital Long Island, United States
Andreas M Papas
East Tennessee State University, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Vladlen Slepak
University of Miami, United States
Huiqin Yang
ICON Clinical Research Ltd, United Kingdom
Saad Tayyab
UCSI University, Malaysia
Alessandro Gallo
Springer Healthcare, Italy
Bernd Blobel
University of Regensburg, Germany
Maria Cristina Gamberini
University of Modena e Reggio Emilia, ItalySubmit your abstract Today
Title : Liver biopsy handling of Metabolic-Associated Fatty Liver Disease (MAFLD): The children's hospital of eastern Ontario grossing protocol
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Haptoglobin-Related Protein Without Signal Peptide as biomarker of renal salt wasting (HPRWSP) in hyponatremia, hyponatremia-related diseases and as new syndrome in alzheimer’s disease
John K Maesaka, NYU Langone Hospital Long Island, United States
Title : Enabling knowledge-driven integration and interoperability in intelligent and ethical transformed health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets. Discovery of agonists and antagonists of OR51E1, an understudied G Protein-Coupled Receptor
Vladlen Slepak, University of Miami, United States
Title : Revolutionizing healthcare and pharma: Artificial intelligence-powered scientific communications and medical writing
Alessandro Gallo, Springer Healthcare, Italy
Title : Understanding drug transport in plasma: the role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model to be set up via biodesign-driven biotech and upgraded biomarketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Cell viability assays under radiofrequency application modulated by nanomaterials
Paulo C De Morais, Catholic University of Brasilia, Brazil
Title : Preparation and characterization of fibers made from PCL/PVP-ChAgG, along with exploring their potential as wound dressings
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Biosimilars - The current progress
Miroslav Radenkovic, University of Belgrade, Serbia